SNYSanofi ADR New York Stock Exchange
Sanofi ADR 54, Rue La Boétie Paris , 75008 http://www.sanofi.comSanofi SA is healthcare company which is engaged in the research, development, manufacture and marketing of therapeutic solutions. It business activities include operations of specialty care, Established Prescription Products and vaccines operations.
- CEO: Olivier Brandicourt
- Employees: 106,566
- Sector: Healthcare
- Industry: Drug Manufacturers
Latest Stocks Posts
Latest news about the SNY
- New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents, and adults Results provide insight into the clinical and real-world experience of Dupixent on key disease measures including itch, disease severity, sleep and anxietyDupixent prView More →
- Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. According to data released at the European Society for Medical Oncology 2021 (ESMO21), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC). The phase 3 Empower-Lung 3 trial included both squamous and nonsquamous NSView More →
- ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC Phase 3 trial met its primary and key secondary endpointsLibtayo is one of two PD-(L)1 inhibitors to demonstrate positive Phase 3 results in first-line advanced NSCLC irrespective of histology both as monotherapy and in combination with chemotherapyTrial enrolled patients with varied baseline characteristics, including squamoView More →
- 5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch
More COVID-19 vaccines could be on the way. While hundreds of millions of people around the world have received shots from the vaccines that are already approved or authorized, several other vaccine candidates are currently in late-stage testing. In this Motley Fool Live video, recorded on Sept. 8, Fool contributors Keith Speights and Brian Orelli discuss five stocks to watch that could be winners if those late-stage clinical trials are successful.View More →
- Doctor: This conversation about boosters doesn’t take place just in the U.S.
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.View More →
- Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics PARIS – September 14, 2021 - Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines and therapies using mRNA technology. The acquisition adds a critical pillar to the company’s mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other straView More →
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Kadmon Holdings, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Kadmon Holdings, Inc. ("Kadmon Holdings" or the "Company") (NASDAQ: KDMN) in connection with the proposed acquisition of the Company by Sanofi ("Sanofi") (NASDAQ: SNY). Under the terms of the merger agreement, the Company's shareholders will receive $9.50 per share in cash for each share of Kadmon Holdings common stock that they hold. The transaction is valued at approximateView More →
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.
Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company by Sanofi (NASDAQ: SNY). Stockholders will receive $9.50 for each share of Kadmon stock that they hold. The transaction is valued at approximately $1.9 billion and is expected to close in the fourth quarter of 2021.View More →
- KADMON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KDMN and Encourages Investors to Contact the Firm
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Kadmon Holdings, Inc. (NASDAQ: KDMN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Sanofi S.A. (NASDAQ: SNY). Click here to learn more and participate in the action. On September 8, 2021, Kadmon announced that it had entered inView More →